Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11989197 | 0.97 | ALDH1A1 (0.43) | ALDH1A1POLBCYP2B6NPC1 | |
| SCHEMBL24663779 | 0.88 | CYP2B6 (0.34) | ALDH1A1POLBCYP2B6NPC1 | |
| SCHEMBL23874582 | 0.81 | ALDH1A1 (0.43) | ALDH1A1POLB | |
| SCHEMBL14584067 | 0.79 | ALDH1A1 (0.42) | ALDH1A1POLB | |
| SCHEMBL14544270 | 0.79 | CYP2B6 (0.31) | ALDH1A1POLBCYP2B6 | |
| SCHEMBL24001047 | 0.79 | ALDH1A1 (0.35) | ALDH1A1POLB | |
| SCHEMBL23710924 | 0.77 | ALDH1A1 (0.41) | ALDH1A1POLB | |
| SCHEMBL20343324 | 0.77 | POLB (0.45) | ALDH1A1POLB | |
| SCHEMBL14544207 | 0.77 | CYP2B6 (0.33) | CYP2B6NPC1 | |
| SCHEMBL13700092 | 0.77 | ALDH1A1 (0.41) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145812-A1 | AMINOAMIDE COMPOUNDS | BIOTHERYX, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-7750007-B2 | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors | SUPERGEN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145812-A1 | AMINOAMIDE COMPOUNDS | DNPEP, BCAT2, AADAT | ALDH1A1 3250/4885POLB 3207/4885CYP2B6 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.